Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Parkinson disease

Intrajejunal duodopa improves nonmotor symptoms

Honig, H. et al. Intrajejunal levodopa infusino in Parkinsons disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord. doi:10.1002/mds.22596

Previous studies have shown that, compared with oral levodopa medication, continuous infusion of levodopa–carbidopa (duodopa) gel reduces motor complications in advanced Parkinson disease (PD). A study by Honig and colleagues has, for the first time, explored the effects of infusion of intrajejunal duodopa on nonmotor symptoms in advanced PD cases.

“Nonmotor symptoms are a key aspect of PD and a major determinant of quality of life and are often under-recognized and under-treated,” describes lead investigator K. Ray Chaudhuri, of Kings College Hospital, London, UK. Chaudhuri explains that his team “led the international development and validation of the first ever nonmotor questionnaire, which empowers the patient to declare the nonmotor symptoms, and the nonmotor scale, which allows the clinician to quantify these problems.”

The investigators monitored 22 patients (mean age 58.6 years) with advanced PD who received intrajejunal duodopa for 6 months. Assessments were made using the nonmotor symptoms scale, the Unified Parkinson's Disease Rating Scale (UPDRS) domain 3 (motor) and 4 (complications), and Parkinson's Disease Questionnaire (PDQ-8) for quality of life.

“The dramatic finding was the overall improvement in nonmotor symptoms including sleep, mood, dribbling of saliva and urinary function,” Chaudhuri comments. The nonmotor symptoms scale also revealed that intrajejunal duodopa conferred a sizeable beneficial effect on cardiovascular, attention and memory, gastrointestinal, and pain symptoms, mirroring the notable improvements in motor state observed on the UPDRS. Furthermore, improvements in quality of life were strongly correlated with the changes in the total nonmotor symptoms scale.

Figure 1: Duodopa® intestinal infusion system (Solvay Pharma AB, Västra Frölunda, Sweden).
figure1

a | Duodopa® container. b | Pump. c | Connection. d | Gastric port. e | Intestinal tubing. Image provided by Prof. K. Ray Chaudhuri.

These data provided by the nonmotor symptoms scale suggest that therapies such as intrajejunal duodopa gel infusion can be considered to treat some nonmotor symptoms as well as motor symptoms in patients with PD, the researchers conclude.

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Richards, L. Intrajejunal duodopa improves nonmotor symptoms. Nat Rev Neurol 5, 354 (2009). https://doi.org/10.1038/nrneurol.2009.84

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing